Monday, November 16, 2026 Vol. I · No. 4
Health · Via STAT

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Image: STAT

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.

This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.

Read the full story at STAT ↗

statnews.com

More from the Health desk